Intermediates of the TCA cycle were altered in our data in bleomycin-treated lungs, as was previously shown in TGFβ1-treated fibroblasts compared to control fibroblasts (Bernard et al., 2018) and in IPF lungs (Kang et al., 2016). This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.